Hantavirus: Three Dead, One Ship, and What the Panic Is Hiding

How the Andes virus actually works, why a pandemic is mathematically improbable, and what public fear has to do with science.

I am currently working on something else entirely, on a scientific paper about DNA evidence and its evidentiary weight in court proceedings, and between two stretches of literature research I pick up my phone, because a brain that has been running at full capacity for several hours occasionally needs a brief moment of distance before the next source is opened. And what I have been reading in those moments, for days now, on every news portal, in every print edition, on every broadcast channel, is the same word: Hantavirus. Three dead. A cruise ship. A WHO warning. And beneath those headlines, in the half-bold subtext that is never fully spelled out but precisely positioned, the implication: this could be the next pandemic.

Those who follow this blog will know that I usually write at the intersections of forensics, law, and technology, fields where I have worked in practice for decades. Some time ago I began to open that frame, because there are subjects that deserve an informed voice regardless of whether they fall within my professional home territory. The hantavirus is one of those subjects, and the reason it has not let me go is not a medical one but a communicative one: it demonstrates with near-textbook clarity how media outlets deploy fear as a steering mechanism, how they select what they name and what they leave unspoken, and how precisely that mechanism functions when a concrete trigger, in this case three deaths aboard a ship, becomes available. I recognize this from forensic work, from expert witness proceedings, from disputes over evidence: the selection of what one shows is at least as powerful as what one says. So I spent several days researching, reading primary literature, verifying numbers, and then I wrote this text.

I have developed one particular habit in dealing with headlines, and I find it genuinely useful: I do not ask what they say, I ask what they leave out. And what the coverage of the past week omits about hantavirus is so decisive for understanding the actual situation that I stopped opening the next research paper and started writing instead. Fear sells well. Clarity requires more space. Both of those things are true, and for that reason this text is not a reassurance, it is an engagement with what the science actually knows.

A Virus That Is Not a Discovery, Because It Was Always There

The hantavirus is not a new pathogen, and anyone reading the current headlines as though it had just been thawed from some Siberian archive and released upon the world should spend a brief moment with the history of science. The family Hantaviridae consists of enveloped, single-stranded negative-sense RNA viruses with a segmented genome organized into three functionally distinct segments: the S segment encodes the nucleoprotein, the M segment encodes the two surface glycoproteins Gn and Gc that mediate receptor binding and cell entry, and the L segment carries the RNA-dependent RNA polymerase, which the virus must bring along itself because host cells possess no equivalent machinery for that function. The family belongs to the order Bunyavirales, a large group of negative-sense RNA viruses that colonize both animal and plant host systems.

The virus takes its name from the Hantan River running between North and South Korea, and that name points to one of the first scientifically consequential outbreaks of the genus. During the Korean War, more than three thousand soldiers fell ill with a severe hemorrhagic fever of unclear etiology that entered the literature as Korean hemorrhagic fever (Schmaljohn & Hjelle, 1997, Hantaviruses: a global disease problem, Emerging Infectious Diseases, 3(2), 95–104). It was not until 1976 that the South Korean physician Ho Wang Lee succeeded in isolating the causative agent, the Hantaan virus, from the striped field mouse Apodemus agrarius, and it took several more years before the full extent of this virus family’s global distribution became visible. Today, more than forty recognized hantavirus species are known, distributed across nearly every continent except Antarctica, and each of those species is bound in a tight, evolutionarily deep-rooted co-evolution with a specific rodent host.

This host-virus co-evolution is the biological foundation on which all epidemiological understanding of hantavirus rests, and it is the reason why the current coverage is simply wrong on one central point. In its natural reservoir, meaning in the mouse, the rat, or the pygmy rice rat, the virus produces no clinical disease. It replicates persistently without causing symptoms, a stable co-existence that has been selected over thousands of years. The human being is an incidental host, one who enters the transmission chain not through biological necessity but through geographic and behavioral proximity to the reservoir, through inhalation of virus-laden aerosols from rodent excreta, through direct contact with contaminated material, or through bites. The virus has no evolutionary interest in humans, because humans represent no reproductive strategy for it.

HFRS and HPS: Two Diseases Sharing One Name

Here lies the first and most consequential error in the current coverage. The term “hantavirus” is used as though it denoted a single clinical phenomenon with a single mortality rate and a single route of transmission. It does not, and the consequence of this simplification is that numbers applying to one specific viral species in one specific geographic context are projected onto a situation to which they do not apply.

Hantavirus infection in humans manifests in two fundamentally different clinical syndromes, geographically clearly separated and caused by distinct virus species. In Europe and Asia, the so-called Old World hantaviruses, primarily the Puumala virus in northern and central Europe, the Hantaan virus in East Asia, and the Dobrava-Belgrade virus in the Balkans, cause hemorrhagic fever with renal syndrome, abbreviated HFRS in the clinical literature. Pathophysiologically, the kidney is the primary target organ: the virus preferentially infects the vascular endothelium of the glomeruli and the peritubular capillaries, producing increased vascular permeability, renal hypoperfusion, and in severe cases acute kidney failure (Jonsson et al., 2010, Hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: a global challenge, Clinical Infectious Diseases, 51(S1), S87–S95). The clinical picture begins with abrupt fever, headache, and myalgia, followed by a hypotensive phase with vascular leakage, subsequent oliguric kidney failure, and, in favorable cases, polyuric recovery. Mortality varies by virus species: the European Puumala virus, which is dominant in Germany, kills in fewer than one-tenth of one percent of cases, while the Hantaan virus in East Asia reaches a case fatality rate of roughly fifteen percent and the southeastern European Dobrava virus up to twelve.

In North and South America, the New World hantaviruses, including the Sin Nombre virus in North America and the Andes virus in South America, produce an entirely different clinical picture: hantavirus cardiopulmonary syndrome, abbreviated HCPS or HPS. Here the lung is the primary target organ, the virus replicates preferentially in the alveolar epithelium and pulmonary endothelium, and what follows is massive capillary leakage with non-cardiogenic pulmonary edema that is clinically indistinguishable from severe ARDS. The prodromal phase lasts three to seven days and looks exactly like influenza: fever, myalgia, fatigue, sometimes gastrointestinal symptoms, with no respiratory signs in this stage. Then comes the cardiopulmonary collapse, often within hours, with bilateral interstitial infiltrates on chest imaging, plummeting oxygen saturation, and cardiogenic shock driven by myocardial depression. The window between “feeling somewhat unwell” and intensive care with mechanical ventilation and, in refractory cases, extracorporeal membrane oxygenation can be less than a single day (Mertz et al., 2006, Hantavirus cardiopulmonary syndrome in Canada, Annals of Internal Medicine, 145(10), 751–757).

This distinction is not academic hairsplitting. It is the reason why the mortality figures currently circulating through the coverage are simply not readable without context.

The Andes Virus and the Property That Changes Everything

The Andes virus, responsible for the outbreak aboard the cruise ship MV Hondius, occupies a unique position among all known hantaviruses for one single, virologically significant reason: it is the only hantavirus species with documented person-to-person transmission. This property was first described in 1996 during an outbreak in El Bolón, Río Negro Province, Argentina, and has since been confirmed through several well-documented clusters (Martinez et al., 2005, Person-to-person transmission of Andes virus, Emerging Infectious Diseases, 11(12), 1848–1853).

The molecular mechanism of this transmission has been studied in considerable detail. Immunocytochemical and ultrastructural investigations have shown that the Andes virus replicates not only in alveolar epithelial cells but also in the secretory cells of the submandibular salivary glands, and that viral particles are actively shed into the alveolar lumen and potentially into saliva (Ferrés et al., 2020, Immunocytochemical and ultrastructural evidence supporting that Andes hantavirus is transmitted person-to-person through the respiratory and/or salivary pathways, Frontiers in Cellular and Infection Microbiology, 9, 435). Concretely, this means that an infected person sheds the virus through respiratory aerosols and possibly through saliva, making aerogenic transmission possible in principle. Research published in 2023 by scientists at the Robert Koch Institute confirmed horizontal virus transmission and efficient viral shedding in the Syrian hamster model, in which Andes virus consistently reproduces the key features of human HCPS (Riesle-Sbarbaro et al., 2023, Human-to-human transmission of Andes virus modeled in Syrian hamsters, Emerging Infectious Diseases, 29(10), doi:10.3201/eid2910.230544).

And yet, precisely here begins the part that the headlines do not tell.

The Ship, the Timeline, and the Facts

On April 1, 2026, the MV Hondius, a vessel sailing under the Dutch flag, departed from the port of Ushuaia in Argentine Patagonia (World Health Organization, 2026, Disease Outbreak News: Hantavirus cluster linked to cruise ship travel, who.int, retrieved May 10, 2026). The route led through the South Atlantic, with stops at the Antarctic Peninsula, South Georgia Island, Tristan da Cunha, Saint Helena, and Ascension Island, some of the most remote maritime regions on the planet. Among the passengers were German, Dutch, British, and other European nationals.

The first critically ill passengers had, by everything the ongoing investigations have established so far, traveled through Patagonian interior terrain before boarding, through areas where the Andes virus is endemic in the local rodent population, specifically in the long-tailed pygmy rice rat Oligoryzomys longicaudatus, the primary reservoir of the virus. On April 24, one adult woman’s condition deteriorated sharply during the stop at Saint Helena; she collapsed during a connecting flight to Johannesburg and died in the emergency department on April 26. Laboratory testing confirmed hantavirus infection on May 2, 2026, and the WHO identified the strain as Andes virus on May 6 (Centers for Disease Control and Prevention, 2026, HAN Health Advisory 528, cdc.gov, retrieved May 10, 2026). As of May 8, 2026, the WHO reports eight cases, six confirmed and two probable, with three deaths. The primary infection most likely occurred through the classic zoonotic route, meaning through exposure to infected rodents on the mainland before boarding. Whether and to what extent person-to-person transmission subsequently occurred aboard the ship remains under active epidemiological investigation and has not been conclusively established. The European Centre for Disease Prevention and Control explicitly classifies the risk to the general population in the EU and EEA as very low (European Centre for Disease Prevention and Control, 2026, Rapid Risk Assessment: Hantavirus cluster linked to cruise ship travel, ecdc.europa.eu, retrieved May 10, 2026).

The Mortality: The Honest Number, Read Correctly

The Andes virus carries a case fatality rate of approximately forty percent, and that is a figure that should not be softened, because softening it here would be intellectually dishonest (Riesle-Sbarbaro et al., 2023, Emerging Infectious Diseases). The United States CDC places the mortality among people who develop respiratory disease following hantavirus infection at thirty-eight percent, consistent with the Andes virus figure across the literature. One in every three to four people who become clinically ill dies. That is the truth, and it has nothing to do with fearmongering; it is a matter of documented fact.

But this number must be read correctly, and “correctly” means: within the conditions that define it. First, this case fatality rate refers to clinically manifest cases, meaning people who become sick severely enough to be diagnosed. Serological studies in endemic regions suggest that a substantial proportion of infections run subclinically or with mild, flu-like symptoms that are never diagnosed and never counted. The true infection fatality rate, meaning mortality in relation to all infections, is therefore likely lower than the case fatality rate. How much lower is difficult to establish in the absence of systematic seroprevalence studies. Second, the Andes virus is geographically confined to South America, bound to its rodent reservoir in the Andean region and Patagonia. Third, and this is the decisive point for any assessment of pandemic potential, a forty-percent case fatality rate is not what makes a virus pandemic.

For comparison: the Ebola virus during the 2014–2016 West Africa epidemic carried a case fatality rate of forty to seventy percent. It did not trigger a pandemic, because its transmission efficiency was too low to sustain spread beyond tight contact clusters. The true driver of pandemic dynamics is not lethality, it is transmission dynamics.

The Mathematics of Panic: Why the Andes Virus Will Not Cause a Pandemic

In epidemiology, the basic reproduction number R₀ describes the average number of secondary infections generated by one infected individual in a fully susceptible population without any protective measures in place. When R₀ exceeds one, an epidemic grows. When it falls below one, the outbreak dies out. That is not a complicated concept; it is a compact analytical tool that one must understand in order to evaluate pandemic potential at all.

For the Andes virus, the only robust, peer-reviewed estimate of R₀ comes from the Epuyén outbreak in Chubut Province, Argentina, between 2018 and 2019, which stands as the best-documented example of sustained person-to-person transmission of ANDV on record. The analysis, published in the New England Journal of Medicine, found a median R₀ of 2.12 before isolation and quarantine measures were introduced (New England Journal of Medicine, 2020, Super-spreaders and person-to-person transmission of Andes virus in Argentina, doi:10.1056/NEJMoa2009040). After those measures were implemented, the value dropped to 0.96, below the critical threshold of one, and the outbreak ended. Eighteen cases were documented in the entire cluster. What is crucial to understand is what generated that R₀ of 2.12 in the first place: three superspreaders, three specific individuals who attended crowded social gatherings while already in the early symptomatic phase. Without that superspreader effect, the reproduction number would have been considerably lower.

For comparison: the original SARS-CoV-2, the Wuhan strain, carried an estimated R₀ of 2.5 to 3.5 (Liu et al., 2020, The reproductive number of COVID-19 is higher compared to SARS coronavirus, Journal of Travel Medicine, 27(2), taaa021). The Delta variant reached approximately 5 to 6, and Omicron surpassed all prior estimates with values between 8 and 15, depending on population context and existing immunity. On paper, an R₀ of 2.12 for the Andes virus looks similar to the original COVID-19 strain, and that is precisely the impression the headlines convey when they use the phrase “person-to-person transmission” without quantifying it.

But the R₀ value alone is insufficient for assessing pandemic potential. The pandemic risk of a pathogen emerges from the interaction of several factors, which can be expressed in simplified form as:

[math]P_{\text{pandemic}} approx R_0 \times T_{\text{eff}} \times (1 – I_{\text{baseline}}) \times M_{\text{global}}[/math]

Here, T_eff represents the transmission efficiency without continued access to the zoonotic source, meaning the capacity of the virus to self-perpetuate through human-to-human chains alone, without ongoing reseeding from the animal reservoir. I_baseline is the existing baseline immunity in the population, and M_global is the mobility multiplier, the degree to which infected individuals can travel globally before becoming symptomatic.

For SARS-CoV-2, all four parameters were simultaneously unfavorable: an R₀ of 2.5 and rising, a T_eff approaching 1.0 because the virus required no animal reservoir for its continued spread, a baseline immunity of zero in a world population encountering an entirely new pathogen, and a presymptomatic infectious period of several days during which infected, still-asymptomatic people moved freely through airports and transit systems.

For the Andes virus, the critical parameter T_eff is extremely low. In its entire documented history, across more than thirty years since person-to-person transmission was first described in 1996, an estimated three hundred such transmission events have been documented worldwide, against approximately three thousand total documented Andes virus infections. Three hundred human-to-human transmission events in three decades, on a planet of nearly eight billion people. Every documented chain of sustained transmission has either had a primary rodent-source infection at its origin or has unfolded under conditions of extreme spatial proximity, among family members, in closed accommodations, or, as in the present case, aboard a vessel with limited space and shared ventilation. A self-sustaining, pandemic-grade spread requires the virus to perpetuate itself from person to person without those starting conditions.

The Andes virus has not achieved this in thirty years of documented observation. And there is no virological finding, no sequence analysis of the ship variant, no evolutionary logic that suggests it is closer to that capacity than it was in 1996 without a fundamental genetic transformation.

What Is Actually Happening in Germany

While international headlines are transporting the Andes virus into German living rooms, a brief look at what hantavirus actually means in Germany is instructive, because it is a fundamentally different picture. The dominant strain in Germany is the Puumala virus, transmitted by the bank vole Myodes glareolus, and it does not cause pulmonary disease but rather the mild to moderate form of HFRS known in Scandinavia as nephropathia epidemica.

Since mandatory reporting was introduced under Germany’s Protection Against Infection Act in 2001, data from the Robert Koch Institute reveal a characteristic pattern: in quiet years, a few hundred cases are reported nationally; in outbreak years, considerably more. In 2010 and 2012, over two thousand and nearly two thousand nine hundred cases were registered nationally, respectively, with over one thousand cases in Baden-Württemberg alone during peak outbreak years. This pattern follows the beech mast cycle: after a prolific mast year, the bank vole population explodes the following year, and with it the exposure density for people in the known endemic regions of Baden-Württemberg, Bavaria, Hesse, and the Osnabrück area. In 2024, 423 cases were reported nationally, and every single one of those patients survived. As of May 4, 2026, forty-six cases had been registered for the current year, with no fatalities. That is the epidemiological reality of hantavirus in Germany: a disease that exists, that warrants genuine attention in specific regions and after beech mast years, but that under the dominant Puumala strain carries a mortality rate below one-tenth of one percent and is routinely managed with supportive therapy, meaning fluid management, dialysis where indicated, and close monitoring. The Andes virus that killed three people in the South Atlantic and the Puumala virus that circulates in German beech forests are, in clinical terms, two entirely different diseases sharing an umbrella name, about as similar as smallpox and chickenpox.

The Therapeutic Vacuum: What It Means, and What It Does Not

At one point, scientific honesty requires a statement that does not lend itself to reassuring formulation. There is no approved antiviral therapy against hantaviruses, and there is no vaccine approved in Europe or the United States. An inactivated whole-virus vaccine against Hantaan virus is available in China and South Korea but has never received international approval because the efficacy evidence was deemed insufficient. Several vaccine candidates against hantavirus species are in clinical development, at least three in phase one and one in phase two-a, but an approved vaccine against the Andes virus is not available for the foreseeable future.

Ribavirin, a nucleoside analogue with broad antiviral activity, is used clinically for HFRS treatment and demonstrates antiviral activity against hantaviruses both in vitro and in animal models, including against the Andes virus when administered intravenously (Mayor et al., 2021, Antiviral efficacy of ribavirin and favipiravir against Hantaan virus, Microorganisms, 9(6), 1306). Favipiravir, a newer antiviral agent against RNA viruses, shows comparable potency in cell culture, and the combination of both substances may have synergistic effects. For HPS, the pulmonary form of Andes virus disease, well-controlled clinical trial data are largely absent, and therapy remains fundamentally supportive in its structure: mechanical ventilation, hemodynamic stabilization with vasopressors, and extracorporeal membrane oxygenation in refractory cases. That is intensive care at the highest level, but it is not an antiviral intervention. This therapeutic gap deserves not panic but considerably more institutional research funding than it currently receives.

Prevention: What Actually Works

The relevant prevention question for the overwhelming majority of people in Germany is not how to protect oneself from the Andes virus but how to minimize contact with Puumala-virus-infected bank voles, and the answer is practically straightforward, if consistently applied. Anyone entering a cellar, woodshed, outbuilding, or other space potentially frequented by rodents should wear an FFP2 respirator and replace dust-raising activities such as sweeping with damp wiping or prior treatment with disinfectant. Rodent infestation in residential buildings should be addressed by professional pest control, and food should be stored in sealed containers. These are not heroic measures, but they are effective, because they interrupt the only relevant exposure pathway.

Those traveling through Patagonian backcountry, meaning through the endemic areas of the Andes virus in Argentina and Chile, should avoid overnight stays in open or poorly sealed field shelters and rigorously avoid contact with rodents and their excreta. Anyone who has had close, sustained contact with a laboratory-confirmed ANDV case should monitor for symptoms throughout the full incubation period of up to eight weeks and seek an informed physician promptly at the first sign of illness. That is sensible behavior in an endemic region, no different from the reasonable precautions one takes with any geographically bounded infectious risk.

Fear as a Control Mechanism: The Last Word

I want to say something here that carries no citation, because it needs none, because anyone who has observed the dynamics of public crisis communication from the inside more than once will confirm it from their own experience. Fear is the most efficient steering instrument that public communication knows. It generates attention without argument, readiness to act without analysis, and it fills column inches without substance. A cruise ship, three deaths, the word “virus” in bold type, and the reader is already carrying the fully assembled catastrophe scenario in their mind before finishing the second paragraph. And when that second paragraph then explains that person-to-person transmission is “possible” and the virus is “fatal in some cases,” both of those things are technically accurate, but everything that would place those statements in proportion is absent.

Here are the proportions, and they deserve to be stated plainly. The Andes virus has, in thirty years of documented person-to-person transmission history, generated an estimated three hundred such transmission events, worldwide, across three decades. SARS-CoV-2 Omicron reached that number in certain European cities within hours of a single December evening in 2021. A reproduction number of 2.12, measured in a superspreader outbreak in a Patagonian village and pushed below one within days by simple quarantine measures, is not the foundation of a pandemic. It is the virological exception, one that deserves to be understood in its exceptional character, not as a harbinger of what awaits humanity in the next wave. Those who reflexively assume the worst each time a name appears on the front page, because they have been trained to do so, because public communication has systematically conditioned that reflex over years, are handing others the controls over their own judgment, and in a world where judgment is a scarce resource, that is not a small concession. The hantavirus deserves informed attention, sound prevention, and far more research investment than it currently receives. What it does not deserve is the next manufactured panic, for which the next headline is already being composed.

References

• Ferrés, M., Vial, C., Marco, C., Yanez, L., Godoy, P., Castillo, C., et al. (2020). Immunocytochemical and ultrastructural evidence supporting that Andes hantavirus is transmitted person-to-person through the respiratory and/or salivary pathways. Frontiers in Cellular and Infection Microbiology, 9, 435. https://doi.org/10.3389/fcimb.2019.00435
• Jonsson, C. B., Figueiredo, L. T. M., & Vapalahti, O. (2010). A global perspective on hantavirus ecology, epidemiology, and disease. Clinical Microbiology Reviews, 23(2), 412–441. https://doi.org/10.1128/CMR.00062-09
• Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine, 27(2), taaa021. https://doi.org/10.1093/jtm/taaa021
• Martinez, V. P., Bellomo, C., San Juan, J., Pinna, D., Forlenza, R., Elder, M., & Padula, P. J. (2005). Person-to-person transmission of Andes virus. Emerging Infectious Diseases, 11(12), 1848–1853. https://doi.org/10.3201/eid1112.050501
• Mayor, J., Engler, O., & Rothenberger, S. (2021). Antiviral efficacy of ribavirin and favipiravir against Hantaan virus. Microorganisms, 9(6), 1306. https://doi.org/10.3390/microorganisms9061306
• Mertz, G. J., Miedzinski, L., Goade, D., Pavia, A. T., Hjelle, B., Kaufman, C. O., et al. (2004). Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clinical Infectious Diseases, 39(9), 1307–1313.
• New England Journal of Medicine. (2020). Super-spreaders and person-to-person transmission of Andes virus in Argentina. https://doi.org/10.1056/NEJMoa2009040
• Riesle-Sbarbaro, S. A., Kirchoff, N., Hansen-Kant, K., Stern, A., Kurth, A., & Prescott, J. B. (2023). Human-to-human transmission of Andes virus modeled in Syrian hamsters. Emerging Infectious Diseases, 29(10). https://doi.org/10.3201/eid2910.230544
• Schmaljohn, C., & Hjelle, B. (1997). Hantaviruses: a global disease problem. Emerging Infectious Diseases, 3(2), 95–104. https://doi.org/10.3201/eid0302.970202
• Centers for Disease Control and Prevention. (2026, May 9). HAN Health Advisory 528: 2026 multi-country hantavirus cluster linked to cruise ship. https://www.cdc.gov/han/php/notices/han00528.html
• European Centre for Disease Prevention and Control. (2026, May 8). Rapid risk assessment: Hantavirus cluster linked to cruise ship travel. ecdc.europa.eu
• World Health Organization. (2026, May 7). Disease outbreak news: Hantavirus cluster linked to cruise ship travel, multi-country. https://www.who.int